immunological disease – Patient Worthy

source: pixabay.com

First Participant Dosed in IMG-004 Trial for Immunological Diseases

Post author:Jessica Lynn
Post published:August 22, 2022
Post category:Ankylosing Spondylitis Multiple Sclerosis

Near the start of August 2022, biotechnology company Inmagene Biopharmaceuticals ("Inmagene") and biopharmaceutical company HUTCHMED shared via news release that the first participant had been dosed in a Phase…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More